Health TrialsbyHealthPanel

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

ConditionsBrain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific
Trial statusRecruiting
Trial phaseNot listed
Trial typeInterventional
Biological sexAll
Age18-120
SponsorBarbara Ann Karmanos Cancer Institute

About this trial

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histologically confirmed solid tumor or hematologic malignancy

Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging

Able to lie still in the PET scanner

Girth and weight must be suitable to enter the gantry

Disqualifiers

None

Trial design

Treatments tested in this trial

  • 3'-deoxy-3'-[18F]fluorothymidine

    Device

    The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Treatment groups

Not listed Participants
are divided into 1 treatment group
Group A: 3'-deoxy-3'-[18F]fluorothymidineExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs

Time frame
at time of PET or CT PET Scan
2

Changes in thymidine kinase, thymidylate synthase, and standardized uptake values

Time frame
before and after therapy

Secondary outcomes

1

FLT PET response rate

Time frame
up to 2 hours during PET scan

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Barbara Ann Karmanos Cancer Institute

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov
Apply now